

Date: February 7, 2024

The General Manager
Corporate relationship department
BSE Limited
 Phiroze Jeejeebhoy Towers,
 Dalal Street, Fort, Mumbai-400 001
Scrip Code: 543904

The Manager,
Listing department,
National Stock Exchange of India Limited
 Exchange Plaza, C-1, Block-G, Bandra-Kurla,
 Complex Bandra (E), Mumbai-400 051
Scrip Symbol: MANKIND

Subject: Proposed sale of certain equity shares of the face value of ₹ 1 each (“Equity Shares”) of Mankind Pharma Limited (“Company”) held by Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of the Company (“Sellers”) in the open market for achieving minimum public shareholding (“Sale”).

Dear Sir/Madam,

In accordance with the requirement of Rule 19(2)(b) and 19(A) of Securities Contracts (Regulation) Rules, 1957 and Regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with para 3(7)(i) of the SEBI Circular No. SEBI/HO/CFD/PoD2/P/CIR/2023/18 dated February 3, 2023 (“Circular”) in connection with manner of achieving minimum public shareholding, we wish to inform the following details with respect to the intention of the Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of the Company for sale of Equity Shares of the Company, as per the following details:

Sr. No	Details of the events to be provided	Particulars
1	Intention of the Promoter(s)/Promoter Group to sell and the purpose of sale	Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of the Company have conveyed to us their intention to sell the Equity Shares to enable us to comply with the requirements of minimum public shareholding.
2	Details of Promoter(s)/Promoter Group, who propose to divest their shareholding	Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of the Company propose to divest part of their shareholding in the Company.
3	Total number of shares and percentage of shareholding proposed to be divested	(i) Mr. Sheetal Arora: Up to 0.45% of the total paid up equity share capital of the Company aggregating to 18,17,070 shares.

MANKIND PHARMA LIMITED



		(ii) Mr. Arjun Juneja: Up to 0.60% of the total paid up equity share capital of the Company aggregating to 24,01,128 shares. (iii) Mrs. Puja Juneja: Up to 0.57% of the total paid up equity share capital of the Company aggregating to 22,71,336 shares.
4	Period within which the entire divestment process will be completed ("Period")	Period beginning from February 8, 2024 or onwards till February 15, 2024 or the actual date of completion of sale of all Equity Shares, in a single or multiple tranche, as mentioned in Sr. No. 3, whichever is earlier.

The aggregate Promoter and Promoter Group shareholding as on February 7, 2024 is 76.50% of the total paid-up equity share capital of the Company. Post completion of the aforesaid sale, the aggregate Promoter and Promoter Group shareholding in the Company would be reduced to 74.88% of the total paid-up equity share capital of the Company.

Undertaking received from the Promoter and Promoter Group of the Company pursuant to paragraph 3(7)(i) of the Circular is enclosed herewith as Annexure - 1.

Kindly take the same on record.

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer
Membership No. A18711

SHEETAL ARORA

Date: February 7, 2024

To
The Company Secretary and Compliance Officer
Mankind Pharma Limited
208, Okhla Industrial Estate, Phase III
New Delhi 110020, Delhi

Sub: Undertaking in connection with the sale of equity shares of the face value of ₹ 1/- each ("Equity Shares") of Mankind Pharma Limited ("the Company") in the open market for achieving minimum public shareholding.

Dear Sir,

In connection with the aforesaid subject and in accordance with the paragraph 3(7)(i) of the SEBI Circular No. SEBI/HO/CFD/PoD2/P/CIR/2023/18 dated February 3, 2023 ("Circular") for achieving minimum public shareholding, I, Sheetal Arora on behalf of all the members of the Promoter and Promoter Group of the Company hereby undertake that:

"I, Sheetal Arora or any person belonging to the Promoter and Promoter Group of the Company, shall not buy any share(s) in the open market on the dates on which the Equity Shares of the Company are being sold by myself, Mr. Arjun Juneja and Mrs. Puja Juneja as specified in the intimation to the BSE Limited and National Stock exchange of India Limited (together, "Stock Exchanges") for the purpose of achieving minimum public shareholding requirements in compliance with the provisions of Rule 19(2)(b) and 19(A) of Securities Contracts (Regulation) Rules, 1957 and Regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015."

This undertaking is issued to enable you to submit to the Stock Exchanges along with the intimation of proposed sale of shares.

Thanking you,
Yours faithfully,



Sheetal Arora
Promoter of Mankind Pharma Limited